Latest Insider Transactions at Laboratory Corp Of America Holdings (LH)
This section provides a real-time view of insider transactions for Laboratory Corp Of America Holdings (LH). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of LABORATORY CORP OF AMERICA HOLDINGS to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of LABORATORY CORP OF AMERICA HOLDINGS's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 04
2023
|
Lance Berberian EVP, CIO & CTO |
BUY
Exercise of conversion of derivative security
|
Direct |
374
+1.83%
|
-
|
|
Feb 04
2023
|
Brian J Caveney EVP, Pres of ED, CMO & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
560
+3.33%
|
-
|
|
Feb 04
2023
|
Peter J Wilkinson SVP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
150
+6.55%
|
-
|
|
Feb 04
2023
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
300
+5.05%
|
-
|
|
Feb 04
2023
|
Amy B. Summy EVP, Chief Marketing Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
267
+28.8%
|
-
|
|
Feb 04
2023
|
Judith C Seltz EVP, CHRO |
BUY
Exercise of conversion of derivative security
|
Direct |
280
+12.96%
|
-
|
|
Feb 03
2023
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
173
-3.14%
|
$43,769
$253.9 P/Share
|
|
Feb 03
2023
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
SELL
Open market or private sale
|
Direct |
324
-4.62%
|
$81,972
$253.9 P/Share
|
|
Feb 02
2023
|
Judith C Seltz EVP, CHRO |
SELL
Payment of exercise price or tax liability
|
Direct |
77
-4.59%
|
$19,558
$254.99 P/Share
|
|
Feb 02
2023
|
Judith C Seltz EVP, CHRO |
BUY
Exercise of conversion of derivative security
|
Direct |
220
+11.59%
|
-
|
|
Feb 02
2023
|
Peter J Wilkinson SVP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
41
-2.02%
|
$10,414
$254.99 P/Share
|
|
Feb 02
2023
|
Peter J Wilkinson SVP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
117
+5.45%
|
-
|
|
Feb 02
2023
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
64
-1.15%
|
$16,256
$254.99 P/Share
|
|
Feb 02
2023
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
237
+4.08%
|
-
|
|
Feb 02
2023
|
Adam H Schechter President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
805
-3.95%
|
$204,470
$254.99 P/Share
|
|
Feb 02
2023
|
Adam H Schechter President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,773
+11.99%
|
-
|
|
Feb 02
2023
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
119
-1.67%
|
$30,226
$254.99 P/Share
|
|
Feb 02
2023
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
BUY
Exercise of conversion of derivative security
|
Direct |
443
+5.85%
|
-
|
|
Feb 02
2023
|
Amy B. Summy EVP, Chief Marketing Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
77
-16.38%
|
$19,558
$254.99 P/Share
|
|
Feb 02
2023
|
Amy B. Summy EVP, Chief Marketing Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
220
+31.88%
|
-
|
|
Feb 02
2023
|
Paul R Kirchgraber CEO, Covance Drug Development |
SELL
Payment of exercise price or tax liability
|
Direct |
141
-1.05%
|
$35,814
$254.99 P/Share
|
|
Feb 02
2023
|
Paul R Kirchgraber CEO, Covance Drug Development |
BUY
Exercise of conversion of derivative security
|
Direct |
443
+3.18%
|
-
|
|
Feb 02
2023
|
Lance Berberian EVP, CIO & CTO |
SELL
Payment of exercise price or tax liability
|
Direct |
102
-0.52%
|
$25,908
$254.99 P/Share
|
|
Feb 02
2023
|
Lance Berberian EVP, CIO & CTO |
BUY
Exercise of conversion of derivative security
|
Direct |
297
+1.48%
|
-
|
|
Feb 02
2023
|
Brian J Caveney EVP, Pres of ED, CMO & CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
144
-0.91%
|
$36,576
$254.99 P/Share
|
|
Feb 02
2023
|
Brian J Caveney EVP, Pres of ED, CMO & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
443
+2.72%
|
-
|
|
Feb 02
2023
|
Glenn A Eisenberg Chief Financial Officer, EVP |
SELL
Payment of exercise price or tax liability
|
Direct |
206
-0.6%
|
$52,324
$254.99 P/Share
|
|
Feb 02
2023
|
Glenn A Eisenberg Chief Financial Officer, EVP |
BUY
Exercise of conversion of derivative security
|
Direct |
767
+2.17%
|
-
|
|
Nov 08
2022
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
SELL
Open market or private sale
|
Direct |
1,116
-14.3%
|
$258,912
$232.67 P/Share
|
|
Nov 07
2022
|
Brian J Caveney EVP, Pres of ED, CMO & CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
894
-5.49%
|
$208,302
$233.77 P/Share
|
|
Nov 07
2022
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
894
-10.28%
|
$208,302
$233.77 P/Share
|
|
Nov 05
2022
|
Brian J Caveney EVP, Pres of ED, CMO & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,010
+10.98%
|
-
|
|
Nov 05
2022
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,010
+18.77%
|
-
|
|
Nov 01
2022
|
Paul R Kirchgraber CEO, Covance Drug Development |
SELL
Payment of exercise price or tax liability
|
Direct |
892
-6.41%
|
$198,024
$222.56 P/Share
|
|
Nov 01
2022
|
Paul R Kirchgraber CEO, Covance Drug Development |
BUY
Exercise of conversion of derivative security
|
Direct |
2,007
+12.6%
|
-
|
|
Nov 01
2022
|
Adam H Schechter President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
893
-4.83%
|
$198,246
$222.56 P/Share
|
|
Nov 01
2022
|
Adam H Schechter President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,007
+9.8%
|
-
|
|
Nov 01
2022
|
Glenn A Eisenberg Chief Financial Officer, EVP |
SELL
Payment of exercise price or tax liability
|
Direct |
5,348
-13.65%
|
$1,187,256
$222.56 P/Share
|
|
Nov 01
2022
|
Glenn A Eisenberg Chief Financial Officer, EVP |
BUY
Exercise of conversion of derivative security
|
Direct |
12,032
+23.49%
|
-
|
|
Sep 26
2022
|
Glenn A Eisenberg Chief Financial Officer, EVP |
SELL
Open market or private sale
|
Direct |
25,000
-14.67%
|
$5,250,000
$210.62 P/Share
|
|
Sep 07
2022
|
Brian J Caveney EVP, Pres of ED, CMO & CSO |
BUY
Open market or private purchase
|
Direct |
44
+0.31%
|
$10,164
$231.2 P/Share
|
|
Aug 03
2022
|
Glenn A Eisenberg Chief Financial Officer, EVP |
SELL
Open market or private sale
|
Direct |
32,100
-14.22%
|
$8,153,400
$254.13 P/Share
|
|
Aug 03
2022
|
Glenn A Eisenberg Chief Financial Officer, EVP |
BUY
Exercise of conversion of derivative security
|
Direct |
32,100
+12.81%
|
$4,750,800
$148.56 P/Share
|
|
Aug 01
2022
|
Peter J Wilkinson SVP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
23
-1.19%
|
$5,911
$257.94 P/Share
|
|
Aug 01
2022
|
Peter J Wilkinson SVP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
817
+12.47%
|
$119,282
$146.59 P/Share
|
|
Aug 01
2022
|
Peter J Wilkinson SVP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
2,576
-26.0%
|
$664,608
$258.54 P/Share
|
|
Jun 07
2022
|
Brian J Caveney EVP, Pres of ED, CMO & CSO |
BUY
Open market or private purchase
|
Direct |
42
+0.3%
|
$10,164
$242.19 P/Share
|
|
Mar 29
2022
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
2,449
-31.66%
|
$678,373
$277.11 P/Share
|
|
Mar 29
2022
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
SELL
Open market or private sale
|
Direct |
2,356
-26.29%
|
$652,612
$277.11 P/Share
|
|
Mar 28
2022
|
Peter J Wilkinson SVP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
915
-19.84%
|
$252,540
$276.42 P/Share
|